Literature DB >> 18816109

Ni(II), Cu(II), and Zn(II) diethyldithiocarbamate complexes show various activities against the proteasome in breast cancer cells.

Boris Cvek1, Vesna Milacic, Jan Taraba, Q Ping Dou.   

Abstract

A series of three complexes with diethyldithiocarbamate ligand and three different metals (Ni, Cu, Zn) was prepared, confirmed by X-ray crystallography, and tested in human breast cancer MDA-MB-231 cells. Zinc and copper complexes, but not nickel complex, were found to be more active against cellular 26S proteasome than against purified 20S proteasome core particle. One of the possible explanations is inhibition of JAMM domain in the 19S proteasome lid.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18816109      PMCID: PMC2574941          DOI: 10.1021/jm8007807

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  30 in total

1.  Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome.

Authors:  Rati Verma; L Aravind; Robert Oania; W Hayes McDonald; John R Yates; Eugene V Koonin; Raymond J Deshaies
Journal:  Science       Date:  2002-08-15       Impact factor: 47.728

2.  Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells.

Authors:  Dazhi Cen; Daniel Brayton; Babbak Shahandeh; Frank L Meyskens; Patrick J Farmer
Journal:  J Med Chem       Date:  2004-12-30       Impact factor: 7.446

3.  The origin of an EPR signal observed in dithiocarbamate-loaded tissues. Copper(II)-dithiocarbamate complexes account for the narrow hyperfine lines.

Authors:  Y Suzuki; S Fujii; T Tominaga; T Yoshimoto; T Yoshimura; H Kamada
Journal:  Biochim Biophys Acta       Date:  1997-06-06

4.  Characterization of an inhibitory metal binding site in carboxypeptidase A.

Authors:  K S Larsen; D S Auld
Journal:  Biochemistry       Date:  1991-03-12       Impact factor: 3.162

5.  Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells.

Authors:  Kenyon G Daniel; Puja Gupta; R Hope Harbach; Wayne C Guida; Q Ping Dou
Journal:  Biochem Pharmacol       Date:  2004-03-15       Impact factor: 5.858

Review 6.  A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites.

Authors:  B Johansson
Journal:  Acta Psychiatr Scand Suppl       Date:  1992

7.  Pyrrolidine dithiocarbamate-zinc(II) and -copper(II) complexes induce apoptosis in tumor cells by inhibiting the proteasomal activity.

Authors:  Vesna Milacic; Di Chen; Lorena Giovagnini; Alejandro Diez; Dolores Fregona; Q Ping Dou
Journal:  Toxicol Appl Pharmacol       Date:  2008-03-28       Impact factor: 4.219

8.  Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease.

Authors:  Sukhdev S Brar; Claude Grigg; Kimberly S Wilson; Walter D Holder; Didier Dreau; Catherine Austin; Mareva Foster; Andrew J Ghio; A Richard Whorton; Grayson W Stowell; Linda B Whittall; Robert R Whittle; David P White; Thomas P Kennedy
Journal:  Mol Cancer Ther       Date:  2004-09       Impact factor: 6.261

9.  Roles of histone acetylation and chromatin remodeling factor in a meiotic recombination hotspot.

Authors:  Takatomi Yamada; Ken-ichi Mizuno; Kouji Hirota; Ning Kon; Wayne P Wahls; Edgar Hartsuiker; Hiromu Murofushi; Takehiko Shibata; Kunihiro Ohta
Journal:  EMBO J       Date:  2004-02-26       Impact factor: 11.598

10.  JAMM: a metalloprotease-like zinc site in the proteasome and signalosome.

Authors:  Xavier I Ambroggio; Douglas C Rees; Raymond J Deshaies
Journal:  PLoS Biol       Date:  2003-11-24       Impact factor: 8.029

View more
  49 in total

1.  Turning tumor-promoting copper into an anti-cancer weapon via high-throughput chemistry.

Authors:  F Wang; P Jiao; M Qi; M Frezza; Q P Dou; B Yan
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

Review 2.  Novel metals and metal complexes as platforms for cancer therapy.

Authors:  Michael Frezza; Sarmad Hindo; Di Chen; Andrew Davenport; Sara Schmitt; Dajena Tomco; Q Ping Dou
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

3.  Association of metals and proteasome activity in erythrocytes of prostate cancer patients and controls.

Authors:  Christine Neslund-Dudas; Bharati Mitra; Ashoka Kandegedara; Di Chen; Sara Schmitt; Min Shen; Qiuzhi Cui; Benjamin A Rybicki; Q Ping Dou
Journal:  Biol Trace Elem Res       Date:  2012-03-16       Impact factor: 3.738

4.  Novel use of old drug: Anti-rheumatic agent auranofin overcomes imatinib-resistance of chronic myeloid leukemia cells.

Authors:  Xin Chen; Xianping Shi; Xuejun Wang; Jinbao Liu
Journal:  Cancer Cell Microenviron       Date:  2014-11-01

Review 5.  Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition.

Authors:  Kush Patel; Zainab So Ahmed; Xuemei Huang; Qianqian Yang; Elmira Ekinci; Christine M Neslund-Dudas; Bharati Mitra; Fawzy Aem Elnady; Young-Hoon Ahn; Huanjie Yang; Jinbao Liu; Qing Ping Dou
Journal:  Future Med Chem       Date:  2018-08-01       Impact factor: 3.808

6.  A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy.

Authors:  C Zhao; X Chen; D Zang; X Lan; S Liao; C Yang; P Zhang; J Wu; X Li; N Liu; Y Liao; H Huang; X Shi; L Jiang; X Liu; Z He; Q P Dou; X Wang; J Liu
Journal:  Oncogene       Date:  2016-04-18       Impact factor: 9.867

7.  Dithiocarbamate-based coordination compounds as potent proteasome inhibitors in human cancer cells.

Authors:  Daniela Buac; Sara Schmitt; George Ventro; Fathima Rani Kona; Q Ping Dou
Journal:  Mini Rev Med Chem       Date:  2012-10       Impact factor: 3.862

Review 8.  Deubiquitinases (DUBs) and DUB inhibitors: a patent review.

Authors:  Pershang Farshi; Rahul R Deshmukh; Joseph O Nwankwo; Richard T Arkwright; Boris Cvek; Jinbao Liu; Q Ping Dou
Journal:  Expert Opin Ther Pat       Date:  2015-06-16       Impact factor: 6.674

9.  Comparative activities of nickel(II) and zinc(II) complexes of asymmetric [NN'O] ligands as 26S proteasome inhibitors.

Authors:  Michael Frezza; Sarmad Sahiel Hindo; Dajena Tomco; Marco M Allard; Qiuzhi Cindy Cui; Mary Jane Heeg; Di Chen; Q Ping Dou; Cláudio N Verani
Journal:  Inorg Chem       Date:  2009-07-06       Impact factor: 5.165

10.  Synthesis, characterization, and antibacterial and anticancer screening of {M(2+)-Co (3+)-M (2+)} and {Co (3+)-M (2+)} (M is Zn, Cd, Hg) heterometallic complexes.

Authors:  Nagendra K Kaushik; Anurag Mishra; Afsar Ali; J S Adhikari; Akhilesh K Verma; Rajeev Gupta
Journal:  J Biol Inorg Chem       Date:  2012-09-23       Impact factor: 3.358

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.